Updated: Apr 15, 2021
Active Surveillance as One of the Favorable Options to Treat Prostate Cancer
Since PSA discovery in 1970 by Dr. Ablin, many still conscientious professional minds have critically followed and scrutinized its 40-year clinical experience and confirmed the prevalence of its much unfortunate professional and industrial misuse and abuse for financial gain, which led him to proclaim such as one of worst medical disasters in history.
To contain such an unexpected PSA disaster, he outcried in public, stating, “I never dreamt that my discovery 4 decades ago would lead to such a profit-driven public health disaster. The medical community must confront reality and stop the inappropriate use of PSA screening. Doing so would save billions of dollars and rescue millions of men from unnecessary debilitating treatment.”
Over the past 5-10 years, many studies have repeatedly urged social and professional attention to rethink how we should use PSA for diagnosing and treating prostate cancer so as to reverse the imposing medical disasters as Dr. Ablin proclaimed. Such social and professional pressure started out in Europe and followed in the United States as evidenced in an article in the 2015 September issue of the Journal of Urology. Nowadays, a recent study in the US concluded some two-thirds of men with newly diagnosed prostate cancer can
be safely followed under active surveillance with repeating PSA and DRE (digital rectal examination) every six months, which coincidentally complemented what was found and concluded in the European study.